Can anemia drug reverse heart damage in kidney patients?
NCT ID NCT07380893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will check how common left ventricular hypertrophy (thickening of the heart muscle) is in people with chronic kidney disease. It will also look at whether treating anemia with erythropoietin can reduce that thickening. About 100 adults with moderate to severe kidney disease will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erythropoietin
- What this could lead to
- If successful, this study could show that treating anemia with erythropoietin helps reduce heart thickening in kidney disease patients.
- What could go wrong
- This is an early observational study with only 100 participants, so results may not apply to everyone. It measures changes but does not prove long-term benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk